Idealpharma
ActiveSummary
The computed 12-month bankruptcy probability of Idealpharma is 1.8% (moderate). The annual accounts of Idealpharma for financial year 2025 show a net loss of 78% of the equity at the start of that year. The 2025 annual accounts show equity of €55,469 and a net result of -€193,427. Equity is growing by about 3.8% per year across the filed financial years. Its solvency ranks better than 18% of 12,724 sector peers (NACE 47, financial year 2025). The company has been active since 2004 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Mandate history
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| Erik Van Nuffel |
|
Owners and capital
Owners
1 ownerChain of control
- AMBIXX
- MEDISYNALL
- Idealpharma
Highest known parent: AMBIXX. The sources do not say who stands above it.
Owners 1
- MEDISYNALLparentSourceaccounts MEDISYNALL 2025100%
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.